We report a prospective 2-year, multicenter study of patients presenting with intermittent claudication (IC; ankle brachial blood pressure index, ABPI ≤ 0.9). Mean age of the 473 patients enrolled was 68 years, 20% were diabetics, 30% had prior symptomatic coronary heart disease (CHD), 7% had prior stroke, and 39% were current smokers. At baseline, 26.2% of patients had BP ≤ 140/85 mm Hg or lower and at 2 years this figure was 32.5% (P = .01). Current smokers had fallen to 27% (from 39%) at 2 years (P < .001). Use of antiplatelet agents, statins, and angiotensin converting enzyme inhibitors increased significantly during the course of the study as did claudication distance. Death and the composite of death, stroke or myocardial infarction (MI), occurred in 8.4% and 11.6% of patients, respectively. Prognosis was worse in patients with prior history of CHD, older age, those with diabetes and a lower ABPI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0003319710387917 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Timely identification of mild cognitive impairment (MCI) is key to early intervention. While primary care providers are the most likely entry point to detect early signs of MCI, their detection rates are low. Building upon a published study, we used electronic health records (EHR) to develop a clinically enhanced MCI risk prediction algorithm.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
STEM Neurology & Neuropsychological0 Research Group Egypt (SNRGE), Port Said, Port Said, Egypt.
Background: Undergoing intense research and investigation, smoking has garnered attention due to its extensive implications for public health, particularly focusing on cardiovascular and pulmonary issues. however In comparison, the neurological effects of nicotine have not yet been thoroughly investigated. Our objective is to investigate the relationship between smoking cigarettes and Alzheimer disease (AD) and possible effects of switching to E-cigarettes.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Background: Currently, most clinical services focus on dementia diagnosis rather than prevention, despite evidence showing benefits of preventative interventions. People often present with memory problems before having dementia, or when in the early stages and are motivated to adopt preventive lifestyle strategies to slow decline. To address gaps in clinical services we set up the Bristol Brain Health Clinic (BHC) in 2017.
View Article and Find Full Text PDFExploring Predictors of Treatment Response to GLP-1 Receptor Agonists for Smoking Cessation.
Nicotine Tob Res
January 2025
Professor and Director of Center for Neurobehavioral Research on Addiction, Louis A. Faillace, M.D., Department of Psychiatry and Behavioral Sciences, UTHealth, McGovern Medical School, 1941 East Road, BBSB, Houston, TX.
Introduction: Understanding predictors of smoking cessation medication efficacy facilitates the ability to enhance treatment effectiveness. In our pilot trial, exenatide, a glucagon-like peptide-1 receptor agonist, adjunct to nicotine patch improved smoking abstinence compared to nicotine patch alone. This secondary analysis explores potential baseline characteristics associated with differential treatment response to exenatide.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!